Concepedia

Mechanism of Vasopeptidase Inhibitor-Induced Plasma Extravasation: Comparison of Omapatrilat and the Novel Neutral Endopeptidase 24.11/Angiotensin-Converting Enzyme Inhibitor GW796406

Anthony C. Sulpizio, Mark Pullen, Richard M. Edwards, James B. Louttit, David P. Brooks

Journal of Pharmacology and Experimental Therapeutics · 2005 · 24 citations · 16 references

References

16

Plasma bradykinin in angio-oedema

Juerg Nussberger, Massimo Cugno, C Amstutz et al. · The Lancet · 1998 · 700 citations

Thrombosis, Vascular Disease, Cardiovascular Disease +8

Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial

William J. Kostis · American Journal of Hypertension · 2004 · 578 citations · Full text

Increased vascular permeability in C1 inhibitor–deficient mice mediated by the bradykinin type 2 receptor

Eun D. Han, Ryan C. MacFarlane, Aideen N. Mulligan et al. · Journal of Clinical Investigation · 2002 · 310 citations · Full text

Vascular Disease, Diminished Vascular Permeability, Pathology +20

Increased vascular permeability in C1 inhibitor–deficient mice mediated by the bradykinin type 2 receptor

Eun D. Han, Ryan C. MacFarlane, Aideen N. Mulligan et al. · Journal of Clinical Investigation · 2002 · 298 citations

Vascular Disease, Diminished Vascular Permeability, Pathology +20

Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors

Albert Adam, Massimo Cugno, Giuseppe A. Molinaro et al. · The Lancet · 2002 · 182 citations

Ace Inhibitors, Medicine, Vascular Pharmacology +5